Drug intelligence / Profile preview

LBL-034

Development stage: Phase 2
Lead developer: LEADS BioLabs
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Injection

Overview

LBL-034 is a humanized IgG1 subtype asymmetric bispecific antibody targeting both GPRC5D and CD3. It is designed to activate T-cells against multiple myeloma by binding to CD3 on T cells and the tumor-associated antigen GPRC5D on myeloma cells, thereby inducing T-cell-mediated killing of cancer cells. Developed by Leads Biolabs, LBL-034 has received FDA orphan drug designation for the treatment of relapsed/refractory multiple myeloma.

Targets

CD3 (T-cell surface glycoprotein CD3)GPRC5D

Beyond the preview

Go deeper on LBL-034.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LBL-034.

Explore the full profile